Efficacy and Safety of Monotherapy with Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study

被引：0
|
作者：
Taylor, Peter C. [1 ]
Schiff, Michael [2 ]
Wang, Qingmin [3 ]
Jiang, Yusang [3 ]
Kurrasch, Regina [4 ]
Daga, Shruti [5 ]
Rao, Ravi [6 ]
Hsu, Benjamin [3 ]
Tak, Paul-Peter [7 ]
机构：
[1] Univ Oxford, Kennedy Inst Rheumatol, NDORMs, Oxford, England
[2] Univ Colorado, Sch Med, Denver, CO USA
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] GlaxoSmithKline, Uxbridge, Middx, England
[6] GSK Med Res Ctr, Stevenage, Herts, England
[7] GlaxoSmithKline, Stevenage, Herts, England
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3222
引用
收藏
页数：3
相关论文
共 50 条
  • [41] CLINICAL AND RADIOGRAPHIC EFFICACY OF SARILUMAB PLUS METHOTREXATE IN BIOLOGIC-EXPERIENCED AND BIOLOGIC-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INTERNATIONAL STUDY
    van der Heijde, D.
    Genovese, M. C.
    Fan, C.
    Fiore, S.
    Decktor, D. L.
    Fleischmann, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 722 - 722
  • [42] AZD9567 VERSUS PREDNISOLONE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP EFFICACY AND SAFETY STUDY
    Van Laar, J. M.
    Lei, A.
    Safy-Khan, M.
    Almquist, J.
    Astbury, C.
    Belvisi, M.
    Platt, A.
    Prothon, S.
    Samuelsson, S.
    Svanberg, P.
    Keen, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 253 - 254
  • [43] SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, LEADS TO IMPROVEMENTS IN WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDY
    Tanaka, Y.
    Aletaha, D.
    Peterson, S.
    Ganguly, R.
    Kurrasch, R.
    Popik, S.
    Agarwal, P.
    Li, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 580 - 580
  • [44] A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis.
    Mease, Philip
    Gottlieb, A. B.
    Berman, A.
    Drescher, E.
    Xing, J.
    Banerjee, S.
    Wong, R.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S423 - S423
  • [45] Safety and Tolerability of Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study
    Sprenger, Till
    Burcklen, Michel
    Freedman, Mark S.
    Fox, Robert
    Havrdova, Eva K.
    Hennessy, Brian
    Hohlfeld, Reinhard
    Lublin, Fred
    Montalban, Xavier
    Pozzilli, Carlo
    Vaclavkova, Andrea
    Scherz, Tatiana
    Linscheid, Philippe
    Pirozek-Lawniczek, Magdalena
    Kracker, Hilke
    Kappos, Ludwig
    NEUROLOGY, 2020, 94 (15)
  • [46] Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
    Sands, Bruce E.
    Irving, Peter M.
    Hoops, Timothy
    Izanec, James L.
    Gao, Long-Long
    Gasink, Christopher
    Greenspan, Andrew
    Allez, Matthieu
    Danese, Silvio
    Hanauer, Stephen B.
    Jairath, Vipul
    Kuehbacher, Tanja
    Lewis, James D.
    Loftus, Edward V., Jr.
    Mihaly, Emese
    Panaccione, Remo
    Scherl, Ellen
    Shchukina, Oksana B.
    Sandborn, William J.
    LANCET, 2022, 399 (10342): : 2200 - 2211
  • [47] Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled study
    Gottlieb, Alice
    Deodhar, Atul
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Barchuk, William
    Hsia, Elizabeth
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB111 - AB111
  • [48] A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naive to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis
    Mease, Philip J.
    van der Heijde, Desiree
    Ritchlin, Christopher T.
    Cuchacovich, Raquel
    Shuler, Catherine L.
    Lee, Chin H.
    Samanta, Suvajit
    Lin, Chen-Yen
    Gladman, Dafna D.
    Vangerow, Harald
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [49] Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
    McInnes, Iain
    Rahman, Proton
    Gottlieb, Alice
    Hsia, Elizabeth
    Kollmeier, Alexa
    Xu, Xie
    Sheng, Shihong
    Jiang, Yusang
    Shawi, May
    Chakravarty, Soumya
    van der Heijde, Desiree
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2777 - 2779
  • [50] EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Mcinnes, I.
    Rahman, P.
    Gottlieb, A. B.
    Hsia, E. C.
    Kollmeier, A.
    Xu, X. L.
    Sheng, S.
    Jiang, Y.
    Shawi, M.
    Chakravarty, S. D.
    Van der Heijde, D.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 783 - 784
12345